Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/115018
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorHu, MQ-
dc.creatorChua, SL-
dc.date.accessioned2025-09-02T00:32:09Z-
dc.date.available2025-09-02T00:32:09Z-
dc.identifier.urihttp://hdl.handle.net/10397/115018-
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.rights© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Hu, M., & Chua, S. L. (2025). Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies. Microorganisms, 13(4), 913 is available at https://dx.doi.org/10.3390/microorganisms13040913.en_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectAntibiotic resistanceen_US
dc.subjectBacteriophageen_US
dc.subjectNanoparticleen_US
dc.subjectAntimicrobial peptidesen_US
dc.subjectCRISPRen_US
dc.titleAntibiotic-resistant pseudomonas aeruginosa: current challenges and emerging alternative therapiesen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume13-
dc.identifier.issue4-
dc.identifier.doi10.3390/microorganisms13040913-
dcterms.abstractAntibiotic-resistant Pseudomonas aeruginosa is a pathogen notorious for its resilience in clinical settings due to biofilm formation, efflux pumps, and the rapid acquisition of resistance genes. With traditional antibiotic therapy rendered ineffective against Pseudomonas aeruginosa infections, we explore alternative therapies that have shown promise, including antimicrobial peptides, nanoparticles and quorum sensing inhibitors. While these approaches offer potential, they each face challenges, such as specificity, stability, and delivery, which require careful consideration and further study. We also delve into emerging alternative strategies, such as bacteriophage therapy and CRISPR-Cas gene editing that could enhance targeted treatment for personalized medicine. As most of them are currently in experimental stages, we highlight the need for clinical trials and additional research to confirm their feasibility. Hence, we offer insights into new therapeutic avenues that could help address the pressing issue of antibiotic-resistant Pseudomonas aeruginosa, with an eye toward practical applications in future healthcare.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationMicroorganisms, Apr. 2025, v. 13, no. 4, 913-
dcterms.isPartOfMicroorganisms-
dcterms.issued2025-04-
dc.identifier.isiWOS:001475410100001-
dc.identifier.eissn2076-2607-
dc.identifier.artn913-
dc.description.validate202509 bcrc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextEnvironment and Conservation Fund (84/2021); Health and Medical Research Fund (HMRF-23220372); Research Centre of Deep Space Explorations (BBFQ and BBCZ); Pneumoconiosis Compensation Fund Boarden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
microorganisms-13-00913.pdf1.23 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.